tbuckley/cabot-search huggingface dataset:
43P Single-arm phase II of desynchronized irinotecan plus bevacizumab, oxaliplatin, 5-fluorouracil, and folinic acid (bFOLFIRINOX-3) administration in chemorefractory metastatic colorectal cancer patients
Authors: F. Ghiringhelli, N. Roussot, A. Bertaut, H. Bellio, L. Bengrine Lefevre, J. Vincent, E. Rederstorff, A. Hennequin, S. Zanetta, A. Hervieu, J-D. Fumet
Journal: Annals of Oncology (2024)
56P Systemic inflammation in liver vs non-liver metastatic microsatellite stable (MSS) colorectal cancer (CRC): An analysis of 2186 patients (pts) from the observational study BMI-QoL and the phase II and III trials MACBETH, MOMA, ATEZOTRIBE, TRIBE, TRIBE2, TRIPLETE
Authors: V. Formica, C. Cremolini, P. Ciracì, R. Intini, W. Ferrari Bravo, C. Boccaccio, N. Pella, G. Tonini, A.A. Prete, A. Taravella, A. Russo, A. Zaniboni, F. Bergamo, C. Damonte, S. Cupini, V. Studiale, R. Cerantola, M. Brugia, L. Salvatore, D. Rossini
Journal: Annals of Oncology (2024)
84P Next-generation sequencing (NGS) in metastatic colorectal cancer (mCRC): Clinical utility in daily practice in a comprehensive cancer centre
Authors: J.C. Ruffinelli Rodriguez, M. Balsa Pena, F. Torrent, D. Lluís Garulo, M. Martinez Villacampa, G. Soler Gonzalez, R. Gallego Sanchez, M. Orrillo Sarmiento, A. Teule, M. Varela, X. Sanjuan, S. Villatoro, N. Ruiz, D. Azuara, D. Cordero, A. Alay Badosa, R.M. Legido-Diaz, L. Raventos, F. Losa, C. Santos Vivas
Journal: Annals of Oncology (2024)
39P Surufatinib plus doublet (FOLFOX/FOLFIRI) or triplet (FOLFOXIRI) chemotherapy as second-line therapy in metastatic colorectal cancer (mCRC): Updated results of a randomized, open-label, phase II trial
Authors: L. Su, P. Lin, F. Huang, Z. Ye, H. Li, C. Zhuo, S. Wei, S. Yu, J. Li, S. Zheng, Y. Hong, L. Zheng, S. Zhao, R. Lin
Journal: Annals of Oncology (2024)
37P Phase II results of the porcupine (PORCN) inhibitor zamaporvint (RXC004) in genetically selected microsatellite stable colorectal cancer patients
Authors: N. Cook, J.A. Bridgewater, M.P. Saunders, S. Kopetz, R. Garcia-Carbonero, S-H. Beom, B.H. O'Neil, R.H. Wilson, J. Graham, J. Maurel, T.W. Kim, I. Chau, S. Saleha, L. Goodwin, D. Wilson, J. Robertson, H. Timmis, E. Asken, S.A. Woodcock, V. Morris
Journal: Annals of Oncology (2024)
54P Phase I dose-escalation study of trifluridine/tipiracil plus XB2001 and bevacizumab in chemorefractory advanced colorectal cancer: The TASKIN study
Authors: N. Roussot, M. Thibaudin, C. Burlot, A. Schmitt, A. Hervieu, H. Bellio, C. Fraisse, A. Lagrange, V.Z. Tharin, S. Zanetta, J. Vincent, L. Bengrine Lefevre, A. Hennequin, G. Constantin, E. Rederstorff, A. Bertaut, V. Derangère, C. Truntzer, J-D. Fumet, F. Ghiringhelli
Journal: Annals of Oncology (2024)
24P Standardizing data collection in adjuvant colon cancer trials: A consensus project from the IDEA and ACCENT international consortia and national experts
Authors: D. Basile, J. Seligmann, G. Argiles Martinez, T. André, C. Gallois, R.M. Goldberg, G. Yothers, A. Sobrero, J. Meyerhardt, I. Souglakos, R. Labianca, D.N. Church, D. Arnold, J. Tie, S. Gill, P. Laurent-Puig, T. Yoshino, S. Lonardi, Q. Shi, J. Taieb
Journal: Annals of Oncology (2024)
73P Efficacy outcomes in ≥70-year-old or younger patients receiving regorafenib-to-trifluridine/tipiracil sequence or vice versa for refractory metastatic colorectal cancer: Findings from the multicenter retrospective “ReTrITA” study
Authors: C. Signorelli, M.A. Calegari, M. Basso, A. Passardi, J. Lucchetti, I.V. Zurlo, C. Morelli, E. Dell'Aquila, D. Gemma, A. Emiliani, G. Arrivi, F. Zoratto, M.G. Chilelli, M.G. Morandi, F. Santamaria, M. Dettori, A. Cosimati, R. Saltarelli, A. Minelli, E.M. Ruggeri
Journal: Annals of Oncology (2024)
91P Clinical outcomes of patients (Pts) with BRAF V600E-mutant metastatic colorectal cancer (mCRC) treated with first-line (1L) chemotherapy regimens
Authors: A. Parikh, J. Tabernero, M.C. Vieira, K. Kponee-Shovein, B. Li, M. Cheng, J. Liu, H. Kang, X. Zhang
Journal: Annals of Oncology (2024)
72P The RAS status change in mCRC after progression on the first-line therapy using the Idylla RT- PCR platform
Authors: H.R. Kourie, Z. Zalaquett, J. Zouein, A. Chebly, L.F. Nasr, F. El Karak, M. Sadek, O. Safar, M. Fouani, N. Bitar, K.M. Kachmar, F.L. Nasr, F.S.S. Farhat, J.A. Makarem, J.G. Kattan
Journal: Annals of Oncology (2024)
55P Safety, efficacy, and biomarkers of ONO-4578, an EP4 antagonist, in combination with nivolumab and chemotherapy in treatment-naive and proficient mismatch repair (pMMR)/microsatellite stable (MSS) metastatic colorectal cancer (mCRC)
Authors: Y. Kagawa, T. Kato, M. Shiozawa, K. Yamaguchi, M. Gotoh, H. Yasui, T. Hamaguchi, H. Hara, T. Yoshino
Journal: Annals of Oncology (2024)
51P Phase II dose expansion study of DSP107, a first-in-class fusion protein targeting CD47 and 4-1BB, in combination with atezolizumab in patients with advanced MSS colorectal cancer
Authors: A. Saeed, J. Zhang, B. Bashir, A. Philipovskiy, R. Chantre, S. Amsili, R. Tabakman, Y. Shwartz, A. Foley-Comer, A. Jimeno
Journal: Annals of Oncology (2024)
81P The role of metastasectomy in patients with early onset metastatic colorectal cancer
Authors: A. Pretta, P. Ziranu, E. Perissinotto, R. Scalia, F. Marmorino, M.C. De Grandis, P. Ciracì, A. Russo, K. Cerma, C. Cavalli, A. Chiaramonte, A. Taravella, V. Pusceddu, R. Giampieri, R. Berardi, S. Lonardi, F. Bergamo, F. Pietrantonio, C. Cremolini, M. Scartozzi
Journal: Annals of Oncology (2024)
45P Neoadjuvant immunotherapy with prolgolimab in locally advanced MSI/dMMR colorectal cancer: Safety and efficacy analysis
Authors: A.A. Zagidullina, O.A. Kuznetsova, A. Tryakin, M. Fedyanin, V. Aliev, O. Malikhova, A. Stroganova, A. Polynovskiy, I. Karasjov, Z. Mamedli
Journal: Annals of Oncology (2024)
67P Relevance of local treatment with curative intent (LT) against metastatic colorectal cancer (mCRC): Findings of a retrospective cohort study at the Comprehensive Cancer Center Munich (CCC MunichLMU)
Authors: J-A. Eisenburger, A. Weber, Y. Wiberg, F. Allmendinger, I.M.M. Kammermeier Wehlau, D. Wagner, A. Reischer, L. Weiss, K. Heinrich, C.B. Westphalen, V. Probst, T. Fey, K. Berger-Thürmel, F. Walter, R. Seidensticker, J. Ricke, M. von Bergwelt, V. Heinemann, J.W. Holch
Journal: Annals of Oncology (2024)
58P Pooled safety and efficacy analysis of trifluridine/tipiracil (FTD/TPI) plus bevacizumab (BEV) for metastatic colorectal cancer (mCRC) using individual patient data (IPD) from five clinical trials
Authors: K. Yamazaki, T. Yamada, Y. Kuboki, E. Oki, T. Yoshino, T. Hamano, T. Kawakami
Journal: Annals of Oncology (2024)
74P Real-world progression-free and overall survival of patients with metastatic colorectal cancer according to first and second-line treatment regimen: PROMETCO study
Authors: M. Koopman, R. Garcia-Carbonero, C. Pinto, A. Mitroshkin, G. Bodoky, F.E. Marti Marti, J.M.R. O'Connor, S. John, J.I. Sgouros, H.F. Mansinho, R. Greil, P-J. Cuyle, S. Plestina, J. Ocvirk, A. Sullivan, E. Choucair, B. Chevallier, J-B. Bachet
Journal: Annals of Oncology (2024)
42P Neoadjuvant tislelizumab combined with CAPOX for MSS/pMMR high-risk locally advanced colon cancer: A single-arm, exploratory phase II clinical study
Authors: M. Lin, Z. Xia, H. Chen, C. Liao, W. Huang, H. Li, J. Huang, M. Liu, R. Song, Y. Xie, X. Zhang, J. Liang, J. Gan, Y. Guo, S. Zhang
Journal: Annals of Oncology (2024)
66P Targeted treatment (TT) after immune checkpoint inhibitors (ICIs) in BRAF V600E mutated (BRAFm) and deficient mismatch repair or microsatellite instability high (dMMR/MSI-H) metastatic colorectal cancer (mCRC)
Authors: M. Ambrosini, D. Tougeron, D.P. Modest, R. Guimbaud, S. Kopetz, M. Decraecker, F. Sclafani, C. Coutzac, A. Lievre, E.L. Alouani, F. Marmorino, S. Pernot, F.A. Sinicrope, M.E. Elez Fernandez, M.M. Germani, F. Pietrantonio, S. Lonardi, P. Parent, C. Gallois, J. Taieb
Journal: Annals of Oncology (2024)
69P Circulating tumor DNA (ctDNA) dynamics in response to hepatic artery infusion pump therapy
Authors: M. Chung, H. Stitzel, M. Lumish, A. Mohamed, D. Bajor, S. Chakrabarti, M.L. Conces, A. Mahipal, S. Tirumani, L. Ocuin, J.E.E. Selfridge
Journal: Annals of Oncology (2024)
32P Patient-reported tolerability of sotorasib (soto) and panitumumab (pani) versus trifluridine/tipiracil (T/T) or regorafenib (rego) in patients (pts) with metastatic colorectal cancer (mCRC) in the CodeBreaK 300 study
Authors: J. Taieb, M. Fakih, L. Salvatore, T. Esaki, D.P. Modest, D. Paez, M.V. Karamouzis, E. Ruiz, T.W. Kim, Y. Kuboki, F.A. Meriggi, D. Cunningham, K-H. Yeh, C. Cremolini, J. Wang, Q. Tran, J. Chao, Z. Chen, F. Pietrantonio
Journal: Annals of Oncology (2024)
64P Long-term response to regorafenib (REG) in patients with metastatic colorectal cancer (mCRC): A systematic literature review (SLR)
Authors: M. Peeters, X. Pan, M. Koufopoulou, M. Arregui, E. Wissinger, H. Ostojic, F. Pisa, R.D. Kim
Journal: Annals of Oncology (2024)
83P Real-world (RW) study of metastatic colorectal cancer (mCRC) patients (pts) with long-term response (LTR) to regorafenib (REG) in the USA: An updated analysis
Authors: R.D. Kim, X. Pan, Y. Zhang, O. Lunacsek, F. Pisa, H. Ostojic, M. Peeters
Journal: Annals of Oncology (2024)
35P Neutropenia and efficacy outcomes in patients with refractory mCRC: A post-hoc analysis of the phase III SUNLIGHT trial
Authors: G. Prager, J. Tabernero, M. Fakih, F. Ciardiello, E. Van Cutsem, L. Roby, W. Yao, E. Choucair, J. Taieb
Journal: Annals of Oncology (2024)
20P Switching to S-1-based adjuvant treatment is feasible in colorectal cancer patients after cardiotoxicity on fluoropyrimidine-based treatment: A retrospective multicentre observational study
Authors: P.J. Osterlund, S. Kinos, P. Halonen, L-M. Soveri, E. Heerva, A. Algars, R. Ristamaki, T. Salminen, M.O. O'Reilly, R.S. McDermott, R. Kallio, R. Röckert, P. Flygare, J-E. Froedin, B. Glimelius
Journal: Annals of Oncology (2024)
10P A placebo-controlled study comparing doses and efficacy of lentinula edodes mycelia for chemotherapy-induced peripheral neuropathy in colorectal cancer: The LEMON trial
Authors: H. Satake, S. Boku, S. Mitani, Maeda K., T. Kudo, M. Gotoh, T. Takagi, H. Kawakami
Journal: Annals of Oncology (2024)
6MO Evaluation of plasma assessed comprehensive genomic profiling before first-line treatment with FOLFIRI plus cetuximab in RAS/BRAFV600E wild type metastatic colorectal cancer patients in the CAPRI 2-GOIM trial
Authors: G. Martini, E. Martinelli, T. Troiani, S. Napolitano, A. Nicastro, E. Maiello, S. Pisconti, E. Tamburini, A. Avallone, R. Bordonaro, C. Lotesoriere, S. Lonardi, D. Iacono, B. Borrelli, P.S. Tagliaferri, G. Tortora, C. Damonte, A. Febbraro, F. Ciardiello, D. Ciardiello
Journal: Annals of Oncology (2024)
9P Positive ad hoc results from neoadjuvant Foxy-5 treatment of colon cancer patients in the ongoing phase II NeoFox study
Authors: R. Salazar Soler, C. Santos Vivas, I. Macias, A. Yubero Esteban, A. Bassam, J. Gallego Plazas, Y. Al-Farhat, A. Cervantes, P. García Alfonso, D. Paez, A. Ruiz-Casado, C. Lopez, P.F. Árkosy, A. Furka, N. Rodriguez-Salas, F.J. Ramos Pascual, A. Cubillo Gracian, E. Hitre, R. Ferreiro Monteagudo, M.A. Salud Salvia
Journal: Annals of Oncology (2024)
1O Chemotherapy and liver transplantation versus chemotherapy alone in patients with definitively unresectable colorectal liver metastases: Updated results from the randomized TRANSMET trial
Authors: R. Adam, C. Piedvache, L. Chiche, E. Salame, V. Granger, M.P. Ducreux, U. Cillo, F. Cauchy, J. Mabrut, C. Verslype, L. Coubeau, J. Hardwigsen, E. Boleslawski, F. Muscari, J. Lerut, L. Grimaldi, F. Lévi, M. Lewin-Zeitoun, M. Gelli
Journal: Annals of Oncology (2024)
7MO Combined analyses of ctDNA and Immunoscore in stage III colon cancer patients: A post hoc analysis of the IDEA-France and -Greece trials
Authors: J. Taieb, I. Souglakos, I. Boukovinas, A. Falcoz, I. Messaritakis, J. Bennouna, P. Artru, F. Pages, C. Louvet, C. Lepere, J.F. Emile, O. Bouche, T. Mazard, S. Sharma, D. Vernerey, T. André, J. Galon, P. Laurent Puig
Journal: Annals of Oncology (2024)
11P Prophylactic hyperthermic intraperitoneal chemotherapy for colon cancer patients at high risk of peritoneal metastases: An individual patient data meta-analysis
Authors: J. Hamm, R. Vandenberg, E-R. Andrinopoulou, E.S. Zwanenburg, G. Musters, P. Tanis, A. Arjona-Sanchez
Journal: Annals of Oncology (2024)
3O PRODIGE 68 - UCGI 38 - SOREGATT: A randomized phase II study comparing the sequences of regorafenib (reg) and trifluridine/tipiracil (t/t) after failure of standard therapies in patients (pts) with metastatic colorectal cancer (mCRC)
Authors: M.P. Ducreux, M. Ben Abdelghani, D. Tougeron, O. Bouche, J. Viaud, F. Khemissa Akouz, J. Martin-Babau, J-B. Bachet, C. Coutzac, H. Castanie, J. Taieb, J.M. Phelip, N. Fares, W. Cacheux, N. Etchepare, D. Botsen, M. Mailleux, M. Chevrot, M-L. Tanguy, A. Parzy
Journal: Annals of Oncology (2024)
2O Health-related quality of life (HRQoL) with first-line (1L) nivolumab (NIVO) plus ipilimumab (IPI) vs chemotherapy (chemo) in patients (pts) with microsatellite instability-high (MSI-H)/mismatch repair-deficient (dMMR) metastatic colorectal cancer (mCRC): CheckMate 8HW
Authors: S. Lonardi, T. André, D. Arnold, R. Garcia-Carbonero, M. Chalabi, M.E. Elez Fernandez, H.J. Lenz, L.H. Jensen, R. Joshi, J.M.L. Roodhart, T. Yoshino, M. Dixon, S.I. Blum, J. Sims, R. Lawrance, F. Taylor, T. Chen, E. Cela, L. Jin, E. Van Cutsem
Journal: Annals of Oncology (2024)
15P Tumoral lymphocytes infiltration and altered repairing protein complex in microsatellite instable colorectal cancer
Authors: M. Sant Albors, M. Balsa Pena, C. Perelló-Fabregat, M. Jimeno, F. Torrent, C. Cofré Muñoz, C. Santos Vivas, J. Linares, N. Mulet Margalef
Journal: Annals of Oncology (2024)
16P Is systemic inflammation related to adjuvant chemotherapy toxicity in colorectal cancer? A real-world data analysis from a local hospital in Portugal
Authors: C.L. Fernandes, M.T. Da Costa, J. Leitebasilio, D. Silva, A.A. Mesquita, M.S. Pinho, C. Sottomayor
Journal: Annals of Oncology (2024)
23P Renal impairment evaluation on postoperative (adjuvant) chemotherapy for colon cancer
Authors: A. Gladys, S. Kozak, A.J. Owczarek, E. Cedrych, Z.I. Niemir, S. Lacki-Zynzeling, A. Chudek, I. Mrochen-Domin, I. Gisterek, J. Chudek
Journal: Annals of Oncology (2024)
18P Clinical outcomes in pT4N0 colon cancer (CC) patients: Data from a large, multicenter, real-word cohort
Authors: V. Daprà, D. Rossini, A. Puccini, F. Schietroma, A. Cosmai, L. Di Francesco, F. Zoratto, M. Costantini, V. Formica, M. Rofei, G. Mauri, E.F. Bonazzina, M. Iaia, C. Signorelli, L. Antonuzzo, C. Damonte, A. Spinelli, G. Tortora, A. Santoro, L. Salvatore
Journal: Annals of Oncology (2024)
5MO Individual patient data (IPD) meta-analysis of randomised phase III trials (RP3) of chemotherapy for resectable colorectal cancer liver metastases (CRCLM): EORTC RP-2145
Authors: G. Bregni, P. Giasafaki, B. Leurquin, N. Takemura, N. Kokudo, K. Hasegawa, Y. Nishioka, T. Aparicio, M. Kadi, D. Tu, C. O'Callaghan, M.E. Mauer, F. Sclafani
Journal: Annals of Oncology (2024)
8MO Neoadjuvant botensilimab (BOT) plus balstilimab (BAL) in resectable mismatch repair proficient and deficient colorectal cancer: NEST-1 clinical trial
Authors: P.M. Kasi, M.D. Jafari, H. Yeo, L. Lowenfeld, U. Khan, A. Nguyen, D. Siolas, B. Swed, S. Khan, M. Wood, A. Ocean, E. Popa, K. Garrett, E. Golden, P. Guniganti, X.K. Zhou, A. Pigazzi, M.A. Shah, E. Hissong, M. Hidalgo
Journal: Annals of Oncology (2024)
22P Analyzing recurrence in colorectal cancer: Is a five years follow-up enough?
Authors: B. de Frutos González, F. Longo Muñoz, M. Viana Aragonés, G. González Martín, J.M.R. Sanz, B.I. Morón, I. Martínez Delfrade, E. Corral de la Fuente, J. Die-Trill, J. Ocaña, R. García Latorre, E. Canales, R. Ferreiro Monteagudo
Journal: Annals of Oncology (2024)
12P The prognostic significance of BRAF mutations in early-stage colon cancer
Authors: L-R. Dubé, M. Dankner, A. Stein, A. Nowakowski, L. Park, J. Magrill, J-M. Romero, M. Sorin, A-M. Lazaratos, P. Kavan, A.A.N. Rose, K. Ma
Journal: Annals of Oncology (2024)
Targeting tumor-associated macrophages with mannosylated nanotherapeutics delivering TLR7/8 agonist enhances cancer immunotherapy
Authors: Bao-Toan Nguyen Dang, Ramesh Duwa, Sooyeun Lee, Taeg Kyu Kwon, Jae-Hoon Chang, Jee-Heon Jeong, Simmyung Yook
Journal: Journal of Controlled Release (2024)
Age-specific SARS-CoV-2 transmission differed from human rhinovirus in households during the early COVID-19 pandemic
Authors: Trisja T Boom, Marieke L A de Hoog, Ilse Westerhof, Vincent Jaddoe, Valerie D Heuvelman, Elandri Fourie, Judith G C Sluiter-Post, Paul Badoux, Sjoerd Euser, Bjorn Herpers, Elisabeth A M Sanders, Dirk Eggink, Chantal Reusken, Louis J Bont, Joanne G Wildenbeest, Marlies A van Houten, Liesbeth Duijts, Patricia C J L Bruijning-Verhagen
Journal: Journal of Infection (2024)
Association of topical corticosteroid use during pregnancy with stillbirth, cesarean delivery, and neonatal health risks in women with psoriasis: A nationwide study in Taiwan
Authors: Chien-Hua Ou, Sheng-Yin To, Hui-Wen Yang, Yi-Hsien Chen, Ya-Chiao Hu, Liang-Hsuan Chen, Yuan-Liang Wen, Li-Ting Kao
Journal: Journal of the American Academy of Dermatology (2024)
The History of Chromosomal Instability in Genome-Doubled Tumors
Authors: Toby M. Baker, Siqi Lai, Andrew R. Lynch, Tom Lesluyes, Haixi Yan, Huw A. Ogilvie, Annelien Verfaillie, Stefan Dentro, Amy L. Bowes, Nischalan Pillay, Adrienne M. Flanagan, Charles Swanton, Paul T. Spellman, Maxime Tarabichi, Peter Van Loo
Journal: Cancer Discovery (2024)

Abstract Tumors frequently display high chromosomal instability and contain multiple copies of genomic regions. Here, we describe Gain Route Identification and Timing In Cancer (GRITIC), a generic method for timing genomic gains leading to complex copy number states, using single-sample bulk whole-genome sequencing data. By applying GRITIC to 6,091 tumors, we found that non-parsimonious evolution is frequent in the formation of complex copy number states in genome-doubled tumors. We measured chromosomal instability before and after genome duplication in human tumors and found that late genome doubling was followed by an increase in the rate of copy number gain. Copy number gains often accumulate as punctuated bursts, commonly after genome doubling. We infer that genome duplications typically affect the landscape of copy number losses, while only minimally impacting copy number gains. In summary, GRITIC is a novel copy number gain timing framework that permits the analysis of copy number evolution in chromosomally unstable tumors. Significance: Complex genomic gains are associated with whole-genome duplications, which are frequent across tumors, span a large fraction of their genomes, and are linked to poorer outcomes. GRITIC infers when these gains occur during tumor development, which will help to identify the genetic events that drive tumor evolution. See related commentary by Taylor, p. 1766
The <i>IDH</i> paradox: Meta-analysis of alkylating chemotherapy in <i>IDH</i>-wild type and -mutant lower grade gliomas
Authors: Connor J Kinslow, Soumyajit Roy, Fabio M Iwamoto, Paul D Brown, David M DeStephano, Peter D Canoll, Summer S Qureshi, Matthew Gallito, Michael B Sisti, Jeffrey N Bruce, David P Horowitz, Lisa A Kachnic, Alfred I Neugut, James B Yu, Minesh P Mehta, Simon K Cheng, Tony J C Wang
Journal: Neuro-Oncology (2024)

Abstract Background IDH-wild type (-wt) status is a prerequisite for the diagnosis of glioblastoma (GBM); however, IDH-wt gliomas with low-grade or anaplastic morphology have historically been excluded from GBM trials and may represent a distinct prognostic entity. While alkylating agent chemotherapy improves overall survival (OS) and progression-free survival (PFS) for IDH-wt GBM and also IDH-mutant gliomas, irrespective of grade, the benefit for IDH-wt diffuse histologic lower-grade gliomas is unclear. Methods We performed a meta-analysis of randomized clinical trials for World Health Organization (WHO) grades 2–3 gliomas (2009 to present) to determine the effect of alkylating chemotherapy on IDH-wt and -mutant gliomas using a random-effects model with inverse-variance pooling. Results We identified 6 trials with 1204 patients (430 IDH-wt, 774 IDH-mutant) that evaluated alkylating chemoradiotherapy versus radiotherapy alone, allowing us to perform an analysis focused on the value of adding alkylating chemotherapy to radiotherapy. For patients with IDH-wt tumors, alkylating chemotherapy added to radiotherapy was associated with improved PFS (HR:0.77 [95% CI: 0.62–0.97], P = .03) but not OS (HR:0.87 [95% CI: 0.64–1.18], P = .17). For patients with IDH-mutant tumors, alkylating chemotherapy added to radiotherapy improved both OS (HR:0.52 [95% CI: 0.42–0.64], P &amp;lt; .001) and PFS (HR = 0.47 [95% CI: 0.39–0.57], P &amp;lt; .001) compared to radiotherapy alone. The magnitude of benefit was similar for IDH-mutant gliomas with or without 1p19q-codeletion. Conclusions Alkylating chemotherapy reduces mortality by 48% and progression by 53% for patients with IDH-mutant gliomas. Optimal management of IDH-wt diffuse histologic lower-grade gliomas remains to be determined, as there is little evidence supporting an OS benefit from alkylating chemotherapy.
Urinary Catheter–Related Vesicoileal Fistula
Authors: Shuai Zuo, Lianjun Lin
Journal: New England Journal of Medicine (2024)

A man with a 5-month history of urethral catheter use had sudden onset of turbid, greenish-yellow urine. CT showed protrusion of the catheter through the bladder wall, and a vesicoileal fistula was seen on laparoscopy (shown in a video).
332P A phase Ib and pharmacodynamic study of nintedanib monotherapy followed by combination therapy of nintedanib and gemcitabine plus nab-paclitaxel for advanced pancreatic cancer
Authors: S. Al Mutar, S. Kazmi, D. Hsiehchen, T. Brown, H. Abunafeesa, N. Verma, M. Beg, L. Khosama
Journal: Annals of Oncology (2024)
338P Heads or tails? In-depth analysis of pancreatic cancer outcomes according to tumour location
Authors: A. Fernandes, A. Lambert, A. Tarabay, A. Hollebecque, C. Smolenschi, M. Valery, T. Pudlarz, A.C. Fuerea, M. Delaye, V. Boige, M.P. Ducreux, A. Boileve
Journal: Annals of Oncology (2024)
394TiP A phase IIIb, single-arm, open-label, multi-center study on durvalumab in combination with gemcitabine-based chemotherapy as first-line treatment for Chinese patients with unresectable biliary tract cancers: TopDouble
Authors: J. Zhou, S. Qin, H. Sun, Y. Yuan, H. Zhao, J. Zhou, Z. Geng, L-X. Liu, X. Ye, M. Gu, Z. Su
Journal: Annals of Oncology (2024)
340P Molecular profiling in pancreatic cancers: Therapeutic and prognostic impact
Authors: A. Tarabay, A. Boileve, C. Smolenschi, L. Antoun, M. Valery, T. Pudlarz, D. Malka, V. Boige, A. Hollebecque, M.P. Ducreux
Journal: Annals of Oncology (2024)
353P Exploring stereotactic body radiotherapy for pancreatic cancer in elderly patients: Insights from a single-center study
Authors: G.M. Petrianni, M. Fiore, E. Onorati, G. D'Ercole, P. Trecca, M. Benincasa, C. Tacconi, E. Ippolito, S. Ramella
Journal: Annals of Oncology (2024)
381P Evaluation of the prognostic impact of circulating free tumor DNA (cftDNA) dynamics in borderline resectable (BR) or locally advanced (LA) pancreatic ductal adenocarcinoma (PDAC)
Authors: G. Grelli, S. Crucitta, V. Genovesi, L. Bartalini, F. Salani, V. Massa, L. Fornaro, F. Mangogna, S. Cesario, L. Bernardini, M. Caccese, J. Graziani, D. Berra, M. Lencioni, G. Masi, R. Danesi, E. Vasile, M. Del Re, C. Vivaldi
Journal: Annals of Oncology (2024)
527P Systematic detection of dihydropyrimidine dehydrogenase (DPD) deficiency using UH2/U ratio in patients with digestive cancers in central Tunisia: Toxicity profile
Authors: M. Mahjoub, I. Belaid, R. Ghammem, A. Gammoudi, M. Nouira, F. Ezzairi, K. Khelifi, M. Hochlaf, I. Chabchoub, A. Laouani, L. Benfatma, S. Saguem, M. Benfredj, S. Benahmed
Journal: Annals of Oncology (2024)
384P Predictive value of Gal1 and sAxL plasma levels in chemotherapy response of pancreatic ductal adenocarcinoma patients
Authors: L. Visa, N. Martínez-Bosch, C. Ventura, P. Garcia, N. Vazquez, L. Barranco, C. Montagut Viladot, P. Navarro
Journal: Annals of Oncology (2024)